Eric Mortensen

1.9k total citations
20 papers, 1.1k citations indexed

About

Eric Mortensen is a scholar working on Surgery, Molecular Biology and Pharmacology. According to data from OpenAlex, Eric Mortensen has authored 20 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Surgery, 4 papers in Molecular Biology and 4 papers in Pharmacology. Recurrent topics in Eric Mortensen's work include Inflammatory mediators and NSAID effects (4 papers), Gastrointestinal motility and disorders (3 papers) and Eosinophilic Esophagitis (3 papers). Eric Mortensen is often cited by papers focused on Inflammatory mediators and NSAID effects (4 papers), Gastrointestinal motility and disorders (3 papers) and Eosinophilic Esophagitis (3 papers). Eric Mortensen collaborates with scholars based in United States, United Kingdom and Germany. Eric Mortensen's co-authors include James A. Bolognese, Thomas Simon, Hui Quan, Loren Laine, Juanita L. Merchant, Christopher J. Hawkey, Aditi Shahane, André Beaulieu, José A. Maldonado‐Cocco and Eduardo Acevedo and has published in prestigious journals such as Journal of Biological Chemistry, Molecular and Cellular Biology and Gut.

In The Last Decade

Eric Mortensen

19 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eric Mortensen United States	15	485	376	240	238	187	20	1.1k
Meena Asmar Denmark	22	660 1.4×	256 0.7×	595 2.5×	35 0.1×	92 0.5×	32	1.7k
Heidi Jänkälä Finland	7	256 0.5×	556 1.5×	207 0.9×	14 0.1×	46 0.2×	8	883
S Papazoglou Greece	12	116 0.2×	323 0.9×	59 0.2×	20 0.1×	130 0.7×	17	740
Hiroto Hayashi Japan	15	290 0.6×	139 0.4×	308 1.3×	51 0.2×	16 0.1×	48	900
Qi Huang China	15	242 0.5×	42 0.1×	263 1.1×	13 0.1×	71 0.4×	41	664
Hongbin Liu China	19	160 0.3×	47 0.1×	442 1.8×	122 0.5×	80 0.4×	43	962
Julia Möllmann Germany	16	194 0.4×	68 0.2×	294 1.2×	22 0.1×	122 0.7×	22	831
Takashi Yamaguchi Japan	17	309 0.6×	33 0.1×	198 0.8×	20 0.1×	47 0.3×	54	807
George Ou Canada	22	366 0.8×	24 0.1×	321 1.3×	193 0.8×	32 0.2×	45	1.0k
Satoshi Aiko Japan	16	356 0.7×	18 0.0×	232 1.0×	44 0.2×	34 0.2×	42	840

Countries citing papers authored by Eric Mortensen

Since Specialization

Citations

This map shows the geographic impact of Eric Mortensen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Mortensen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Mortensen more than expected).

Fields of papers citing papers by Eric Mortensen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Mortensen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Mortensen. The network helps show where Eric Mortensen may publish in the future.

Co-authorship network of co-authors of Eric Mortensen

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Mortensen. A scholar is included among the top collaborators of Eric Mortensen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Mortensen. Eric Mortensen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Simpson, Eric L., Jonathan I. Silverberg, Margitta Worm, et al.. (2024). Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology. 90(6). 1190–1199. 21 indexed citations

Rothenberg, Marc E., Evan S. Dellon, Albert J. Bredenoord, et al.. (2024). A213 DUPILUMAB EFFICACY IN EOSINOPHILIC ESOPHAGITIS PERSISTS FOR HISTOLOGIC, SYMPTOMATIC, AND ENDOSCOPIC OUTCOMES REGARDLESS OF CONCOMITANT HIGH-DOSE PROTON PUMP INHIBITOR USE. Journal of the Canadian Association of Gastroenterology. 7(Supplement_1). 168–169. 1 indexed citations

Ebisawa, Motohiro, Yoko Kataoka, Akio Tanaka, et al.. (2024). Efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: A randomized, double-blind, placebo-controlled phase 3 study. Allergology International. 73(4). 532–542. 5 indexed citations

Murrell, Dédée F., P. Joly, Victoria P. Werth, et al.. (2024). Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT. Advances in Therapy. 41(7). 2991–3002. 15 indexed citations

Dellon, Evan S., Marc E. Rothenberg, Mirna Chehade, et al.. (2024). A Phase 2/3 Study To Assess The Efficacy And Safety Of Dupilumab Versus Placebo In Adults And Adolescents With Eosinophilic Gastritis With Or Without Eosinophilic Duodenitis. Journal of Allergy and Clinical Immunology. 153(2). AB201–AB201.

Bredenoord, Albert J., Evan S. Dellon, Ikuo Hirano, et al.. (2023). Dupilumab demonstrated efficacy and was well tolerated regardless of prior use of swallowed topical corticosteroids in adolescent and adult patients with eosinophilic oesophagitis: a subgroup analysis of the phase 3 LIBERTY EoE TREET study. Gut. 73(3). 398–406. 19 indexed citations

Vogelmeier, Claus, Mona Bafadhel, Stephanie A. Christenson, et al.. (2023). EFFICACY AND SAFETY OF DUPILUMAB FOR COPD WITH TYPE 2 INFLAMMATION. CHEST Journal. 164(4). A6531–A6534. 1 indexed citations

Jansen, Jan‐Peter, Daniel Lorch, Ben Lasko, et al.. (2011). A Randomized, Placebo-Controlled Phase 3 Trial (Study SB-767905/012) of Alvimopan for Opioid-Induced Bowel Dysfunction in Patients With Non-Cancer Pain. Journal of Pain. 12(2). 185–193. 59 indexed citations

Irving, Gordon, Brian Ramjattan, Michael J. Cousins, et al.. (2011). A Randomized, Placebo-Controlled Phase 3 Trial (Study SB-767905/013) of Alvimopan for Opioid-Induced Bowel Dysfunction in Patients With Non-Cancer Pain. Journal of Pain. 12(2). 175–184. 59 indexed citations

10.

Büchler, Markus W., J. R. T. Monson, Y Flamant, et al.. (2008). Clinical trial: alvimopan for the management of post‐operative ileus after abdominal surgery: results of an international randomized, double‐blind, multicentre, placebo‐controlled clinical study. Alimentary Pharmacology & Therapeutics. 28(3). 312–325. 109 indexed citations

11.

Webster, Lynn R., John F. Peppin, Ben Lasko, et al.. (2008). Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: Results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain. 137(2). 428–440. 115 indexed citations

12.

Hawkey, Christopher J., et al.. (2001). Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials. Alimentary Pharmacology & Therapeutics. 15(10). 1593–1601. 49 indexed citations

13.

Hawkey, C J, L. Jackson, S. E. Harper, et al.. (2001). The gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase‐2, in humans. Alimentary Pharmacology & Therapeutics. 15(1). 1–9. 41 indexed citations

14.

Hunt, Richard H., Barry M. Bowen, Eric Mortensen, et al.. (2000). A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects. The American Journal of Medicine. 109(3). 201–206. 63 indexed citations

15.

Hawkey, Christopher J., Loren Laine, Thomas Simon, et al.. (2000). Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial. Arthritis & Rheumatism. 43(2). 370–370. 280 indexed citations

16.

Laine, Loren, C J Hawkey, Sara A. Harper, et al.. (1999). No evidence of H pylori-NSAID interaction in ulcer formation Results of double-blind, placebo-controlled trials. 2. 228. 12 indexed citations

17.

Mortensen, Eric, et al.. (1997). Epidermal Growth Factor and Okadaic Acid Stimulate Sp1 Proteolysis. Journal of Biological Chemistry. 272(26). 16540–16547. 55 indexed citations

18.

Mortensen, Eric, et al.. (1997). Overexpression of ZBP-89, a Zinc Finger DNA Binding Protein, in Gastric Cancer. Biochemical and Biophysical Research Communications. 233(1). 154–160. 41 indexed citations

19.

Merchant, Juanita L., Brigit R. Taylor, Eric Mortensen, et al.. (1996). ZBP-89, a Krüppel-Like Zinc Finger Protein, Inhibits Epidermal Growth Factor Induction of the Gastrin Promoter. Molecular and Cellular Biology. 16(12). 6644–6653. 114 indexed citations

20.

Merchant, Juanita L., et al.. (1995). Epidermal Growth Factor Stimulation of the Human Gastrin Promoter Requires Sp1. Journal of Biological Chemistry. 270(11). 6314–6319. 77 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact